Open AccessPharmacokinetics of Emtricitabine, Tenofovir, and GS-9137 Following Coadministration of Emtricitabine/Tenofovir Disoproxil Fumarate and Ritonavir-Boosted GS-9137
Author(s) -
S. Ramanathan,
Gong Shen,
Andrew Cheng,
Brian P. Kearney
Publication year - 2007
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0b013e318050d88c
Subject(s) - emtricitabine , cmax , pharmacokinetics , pharmacology , ritonavir , bioequivalence , cmin , medicine , crossover study , confidence interval , adverse effect , dosing , human immunodeficiency virus (hiv) , viral load , placebo , virology , antiretroviral therapy , alternative medicine , pathology
To evaluate the potential for clinically relevant drug-drug interaction between emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) and the ritonavir-boosted HIV integrase inhibitor GS-9137 (GS-9137/r).